Concepts (51)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 6 | 2024 | 226 | 1.330 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2021 | 20 | 0.940 |
Why?
|
| Linezolid | 4 | 2024 | 22 | 0.800 |
Why?
|
| Antitubercular Agents | 6 | 2024 | 322 | 0.720 |
Why?
|
| Diarylquinolines | 5 | 2024 | 39 | 0.670 |
Why?
|
| Nitroimidazoles | 4 | 2024 | 24 | 0.620 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2023 | 329 | 0.280 |
Why?
|
| Treatment Outcome | 3 | 2022 | 889 | 0.240 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2023 | 47 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 253 | 0.210 |
Why?
|
| Granuloma | 1 | 2021 | 3 | 0.200 |
Why?
|
| Humans | 9 | 2024 | 14537 | 0.160 |
Why?
|
| Anti-HIV Agents | 2 | 2016 | 1324 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2016 | 120 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 143 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2020 | 324 | 0.120 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 278 | 0.120 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2014 | 10 | 0.110 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 33 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 37 | 0.110 |
Why?
|
| Pericarditis, Tuberculous | 1 | 2013 | 8 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 472 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 279 | 0.100 |
Why?
|
| Rifampin | 2 | 2023 | 197 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 5913 | 0.090 |
Why?
|
| Middle Aged | 3 | 2024 | 3601 | 0.080 |
Why?
|
| HIV Infections | 3 | 2016 | 5097 | 0.080 |
Why?
|
| Male | 4 | 2024 | 6754 | 0.070 |
Why?
|
| Female | 4 | 2024 | 9103 | 0.060 |
Why?
|
| Young Adult | 2 | 2024 | 2498 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 2985 | 0.060 |
Why?
|
| Child | 2 | 2023 | 2242 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2024 | 115 | 0.060 |
Why?
|
| Aminoglycosides | 1 | 2022 | 5 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2016 | 656 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2022 | 20 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 135 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2022 | 225 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 32 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 127 | 0.040 |
Why?
|
| South Africa | 2 | 2024 | 7596 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2022 | 543 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 175 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 799 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 61 | 0.030 |
Why?
|
| Pericardiocentesis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 6 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1160 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 819 | 0.030 |
Why?
|
| HIV-1 | 1 | 2016 | 1260 | 0.020 |
Why?
|